ClinicalTrials.gg
Not yet recruitingNCT07941999NLRP3Updated Nov 17, 2026

Linking Postoperative Pain, GCF NLRP3 , and Treatment Success Following MTA Full Pulpotomy Vs Root Canal Treatment in Symptomatic Irreversible Pulpitis

An interventional study of full pulpotomy using MTA and Non surgical root canal treatment in Symptomatic Irreversible Pulpitis (SIP), sponsored by Cairo University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

To compare MTA full pulpotomy with conventional non-surgical root canal treatment in mature mandibular permanent molars with symptomatic irreversible pulpitis. The comparison covers postoperative pain, analgesic consumption, change in GCF NLRP3 levels, and clinical and radiographic success. A further aim is to assess whether changes in GCF NLRP3 are related to pain and to success.

Read the detailed description

Aim: To compare MTA full pulpotomy with conventional non-surgical root canal treatment in mature mandibular permanent molars with symptomatic irreversible pulpitis. The comparison covers postoperative pain, analgesic consumption, change in GCF NLRP3 levels, and clinical and radiographic success. A further aim is to assess whether changes in GCF NLRP3 are related to pain and to success.

Methods: This is a two-arm, parallel, assessor-blinded, randomized trial conducted at the Endodontic clinic, Faculty of Dentistry, Cairo University. Sixty patients with a periapical index score ≤ 2 will be randomized to receive either full pulpotomy with MTA or single-visit root canal treatment (n=30 per group). The primary outcome is postoperative pain at 24 hours on an 11-point Numerical Rating Scale. Secondary outcomes are:

pain at 6, 12, 48 and 72 hours and on day 7; number of ibuprofen 400 mg tablets taken over 7 days; GCF NLRP3 levels measured by ELISA preoperatively from tooth and healthy contralateral (internal control) and on day 7 from tooth; clinical and radiographic success at 6 and 12 months.

Analysis will follow the intention-to-treat principle, using the independent-samples t-test or Mann-Whitney U test, the chi-square or Fisher's exact test, and Spearman's rank correlation, with significance set at P ≤ 0.05.

Expected significance: The trial will show whether a simpler, pulp-preserving procedure offers pain and success outcomes comparable to root canal treatment, and whether GCF NLRP3 can serve as a chairside biomarker of healing.

Keywords: symptomatic irreversible pulpitis; full pulpotomy; mineral trioxide aggregate; root canal treatment; postoperative pain; NLRP3 inflammasome; gingival crevicular fluid

02

Conditions studied

  • Symptomatic Irreversible Pulpitis (SIP)
03

In context

Lead sponsor

Cairo University is the lead sponsor of 4,956 studies on the registry; 1,466 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 18-40 years old.
  • Male or female
  • Mandibular molars with SIP: preoperative sharp, moderate or severe pain, with normal periapical radiographic appearance or slight widening(PAI ≤ 2)
  • Systemically healthy () or controlled disease (ASA II)
  • Able to understand NRS and sign
  • Good oral hygiene, with no plaque or calculus, no bleeding on probing (BOP

Exclusion criteria

Exclusion Criteria:

  • Medically compromised patients with significant systemic disorders ()
  • History of intolerance to NSAIDs/ Use of ibuprofen in the last 12 hours
  • Two or more adjacent teeth requiring endodontic treatment
  • External or internal root resorption
  • Vertical root fracture
  • Periapical lesion
  • Controlled diabetes \& smoking
  • Acute periapical abscess or acute exacerbation of a chronic abscess
  • Pregnancy
  • Long-term use
  • Mobility grade II or III
  • Previous root canal therapy
  • Non-restorability
  • TMJ problems, bruxism, clenching or traumatic occlusion
  • Inability to perceive given instructions
  • Antibiotic intake during the 10 days before treatment (may alter GCF inflammatory mediators)
  • Gingival bleeding (gingivitis), recession > 3 mm or pocketing at the GCF sampling sites of the study or contralateral tooth
  • Absent contralateral tooth, or one that is carious, deeply restored or endodontically treated (it is the GCF control)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Non-surgical root canal treatment

    Canals explored with k-file #08 \& #10 hand files; WL with EAL, confirmed radiographically. Irrigation 3 mL of 2.5% NaOCl after every instrument, side-vented needle placed 2 mm from the apex to limit apical extrusion. Instrumentation Single visit; crown-down with DOTA rotary files; EDTA gel in continuous brushing motion. Shaping sequence * 17/.08 (19 mm)→orifice opener * 17/.03→ rotary glide path * 20/.04, #25/.04, #30/.04 and #35/.04; canals dried with sterile paper points. Obturation MC radiograph within 0.5-1 mm of radiographic apex; CLC with ADseal resin sealer. 6 Coronal seal \& baseline film Same GIC base \& bonded composite as pulpotomy group; immediate postoperativeradiograph

    Procedure: full pulpotomy using MTA

  • Experimental
    full pulpotomy with MTA

    After caries removal and de-roofing, the entire coronal pulp is amputated to the canal orifices with a sterile sharp excavator; chamber rinsed with 2.5% NaOCl. 2 Haemostasis Cotton pellet soaked in 2.5% NaOCl on radicular stumps with light pressure for 2 min, then inspect; repeat up to 10 min in total. Achieved when no fresh bleeding comes from any orifice. Time to haemostasis (min) recorded. 3 Pulp capping \& restoration MTAputty , 2-3 mm over stumps and chamber floor, adapted with a moist pellet. After 10 min: glass-ionomer layer, then bonded resin composite in same visit. ! If haemostasis is not achieved Bleeding not controlled within 10 min, or necrotic / non-bleeding radicular pulp → pulpectomy and RCT in the same visit (comparator protocol). Not withdrawn: recorded as a protocol deviation and counted as a pulpotomy failure (ITT); per-protocol sensitivity analysis excludes these cases.

    Procedure: Non surgical root canal treatment

Interventions

  • Procedurefull pulpotomy using MTA

    After caries removal and de-roofing, the entire coronal pulp is amputated to the canal orifices with a sterile sharp excavator; chamber rinsed with 2.5% NaOCl. Haemostasis Cotton pellet soaked in 2.5% NaOCl on radicular stumps with light pressure for 2 min, then inspect; repeat up to 10 min in total. Achieved when no fresh bleeding comes from any orifice. Time to haemostasis (min) recorded. Pulp capping \& restoration MTAputty , 2-3 mm over stumps and chamber floor, adapted with a moist pellet. After 10 min: glass-ionomer layer, then bonded resin composite in same visit If haemostasis is not achieved Bleeding not controlled within 10 min, or necrotic / non-bleeding radicular pulp → pulpectomy and RCT in the same visit (comparator protocol). Not withdrawn: recorded as a protocol deviation and counted as a pulpotomy failure (ITT); per-protocol sensitivity analysis excludes these cases.

  • ProcedureNon surgical root canal treatment

    Canals explored with k-file #08 \& #10 hand files; WL with EAL, confirmed radiographically. 2 Irrigation 3 mL of 2.5% NaOCl after every instrument, side-vented needle placed 2 mm from the apex to limit apical extrusion. 3 Instrumentation Single visit; crown-down with DOTA rotary files; EDTA gel in continuous brushing motion. 4 Shaping sequence * 17/.08 (19 mm)→orifice opener * 17/.03→ rotary glide path * 20/.04, #25/.04, #30/.04 and #35/.04; canals dried with sterile paper points. 5 Obturation MC radiograph within 0.5-1 mm of radiographic apex; CLC with ADseal resin sealer. Coronal seal \& baseline film Same GIC base \& bonded composite as pulpotomy group; immediate postoperativeradiograph

    Also known as: conventional root canal treatment

06

What researchers measure

Primary outcomes

  1. postoperative pain after 24 hours

    using 11-point numeric rating scale (NRS) to score postoperative pain after 24 where 0 means no pain and 10 is worst imaginable pain

    Time frame: 24 hours

Secondary outcomes

  1. postoperative pain after 6,12,48,72 and 7 days

    using 11-point numeric rating scale (NRS) to score postoperative pain after 6, 12, 48,72 hours and 7 days where 0 means no pain and 10 is worst imaginable pain.

    Time frame: 6, 12, 48,72 hours and 7 days

  2. GCF levels of NLRP3

    using ELISA to detect levels of NLRP3 from gingival crevicular fluid

    Time frame: preoperative and 7 days postoperative

  3. Clinical and radiographic success

    Evaluating clinical success ( absence of pain, swelling , sinus tract/ fistula, and tooth is functional) and radiographic success ( absence of periapical radiolucency, internal/ external resorption)

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Publications

  • Neha N, Abraham D, Goyal A, Gupta A, Sharma R, Malhotra RK. GCF NLRP3 as a Biomarker for Assessing Endodontic Treatment Outcomes in Symptomatic Irreversible Pulpitis: A Comparative Nonrandomized, Observational Cross-Sectional Study. J Int Soc Prev Community Dent. 2025 Oct 4;15(5):415-425. doi: 10.4103/jispcd.jispcd_31_25. eCollection 2025 Sep-Oct. PubMed 41244655 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941999
Lead sponsor
Cairo University
Responsible party
Bassant Yasser Shaker Ibrahim El-Saharty (Assistant lecturer of Endodontics, Cairo University) — Principal investigator
First posted
Nov 17, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion